Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Equidyne upbraids Rosch for INJEX claims:

This article was originally published in Clinica

Executive Summary

Equidyne of San Diego, US, has responded to an announcement by Rosch Medizintechnik (Frankfurt, Germany) regarding the INJEX reusable needle-free injection system. Rosch said that it had received US FDA 510(k) approval for the system and would be able to market it in the US. Equidyne says that it owns all US patents covering the INJEX technology and that Rosch, which has European marketing rights, has no US marketing rights other than for INJEX growth hormone. Rosch, which was spun out of Equidyne in 2000, sold exclusive worldwide distribution rights to INJEX for the delivery of hormone deficiency products to an unnamed pharmaceutical company in March, which entailed a $254,000 payment to Equidyne.

You may also be interested in...



Senate Drug Pricing Bill Lowers Manufacturer Discounts In Part D Catastrophic Phase

Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.

Performance Criteria Issued On Magnetic Resonance Coils In New FDA Draft Guidance

Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.

Global Scare Over Nitrosamine Impurities Extends To Diabetes Medication

Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.

Topics

UsernamePublicRestriction

Register

MT068375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel